Evidence map›Paper›PMID 38503927›Full record

Trial reportMolecular psychiatry2024

Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features.

Helena K Kim, Aristotle N Voineskos, Nicholas H Neufeld, George S Alexopoulos, Kathleen S Bingham, Alastair J Flint, Patricia Marino, Anthony J Rothschild, Ellen M Whyte, Benoit H Mulsant

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Molecular psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Helena K KimDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Aristotle N VoineskosDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-0156-0395
Nicholas H NeufeldDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-8046-0212
George S Alexopoulos *Department of Psychiatry, Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital, Westchester Division, New York, NY, USA.ORCID 0000-0001-5677-7001
Kathleen S Bingham *Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Alastair J Flint *Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Patricia Marino *Department of Psychiatry, Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital, Westchester Division, New York, NY, USA.
Anthony J Rothschild *University of Massachusetts Chan Medical School and UMass Memorial Health Care, Worcester, MA, USA.
Ellen M Whyte *Department of Psychiatry, University of Pittsburgh School of Medicine and UPMC Western Psychiatric Hospital, Pittsburgh, PA, USA.
Benoit H MulsantDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. benoit.mulsant@utoronto.ca.ORCID 0000-0002-0303-6450
Centre for Addiction and Mental Health · CANewYork–Presbyterian Hospital · USUniversity Health Network · CAUMass Memorial Health Care · USUniversity of Pittsburgh · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some data suggest that antipsychotics may adversely affect brain structure. We examined the relationship among olanzapine exposure, relapse, and changes in brain structure in patients with major depressive disorder with psychotic features. We analyzed data from the Study of the Pharmacotherapy of Psychotic Depression II trial (STOP-PD II), a randomized, placebo-controlled trial in patients with psychotic depression who attained remission on sertraline and olanzapine and were randomized to continue sertraline plus olanzapine or placebo for 36 weeks. Olanzapine steady state concentration (SSC) were calculated based on sparsely-sampled levels. Rates of relapse and changes in brain structure were assessed as outcomes. There were significant associations between dosage and relapse rates (N = 118; HR = 0.94, 95% CI [0.897, 0.977], p = 0.002) or changes in left cortical thickness (N = 44; B = -2.0 × 10

Indexed as

Antipsychotic AgentsBrainMajor Depressive DisorderOlanzapineRecurrenceSertralineAdultBenzodiazepinesDouble-Blind MethodFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPsychotic DisordersTreatment OutcomeAntipsychotic AgentsBenzodiazepinesOlanzapineSertraline

Identifiers

PMID38503927
OpenAlexW4392953164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.